Becton, Dickinson and Company (BDX)
Franklin Lakes, NJ, US
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
4 articles
- Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? Zacks Investment Research
- 5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years Fool - Investing News
- Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom The Motley Fool
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026 PRNewsWire
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1972-09-14 | — | Active |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.20% | -5.20% | -7.18% | -19.49% | -5.22% | -6.17% | +3.84% | -27.89% | -22.76% | +11.66% | +519.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | +1 |
| Hold | 9 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
167.00
+8.6%
|
| Last Quarter | 6 |
174.17
+13.2%
|
| Last Year | 10 |
170.54
+10.9%
|
| All Time | 31 |
203.39
+32.2%
|
-
Revenue growth Medical - Instruments & Supplies: +7.9%+8.2% ★ Q1'26: -10.6% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-0.5% Q1'26: -203.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+11.8% Q1'26: +11.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+11.4% Q1'26: +4.0% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.1% Q1'26: +1.1% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.3% ★ Q1'26: -3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.87× Q1'26: 22.86× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2011 actual |
Sep 2012 actual |
Sep 2013 actual |
Sep 2014 actual |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 9 Rev. Ana. 8 EPS Ana. |
Sep 2027 9 Rev. Ana. 8 EPS Ana. |
Sep 2028 9 Rev. Ana. 1 EPS Ana. |
Sep 2029 7 Rev. Ana. 1 EPS Ana. |
Sep 2030 8 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.58B
est: 7.36B (+3.0%)
|
7.71B
est: 7.61B (+1.3%)
|
8.05B
est: 7.82B (+3.0%)
|
8.45B
est: 8.26B (+2.3%)
|
10.28B
est: 10.27B (+0.2%)
|
12.48B
est: 12.49B (-0.1%)
|
12.09B
est: 12.07B (+0.2%)
|
15.98B
est: 15.95B (+0.2%)
|
17.29B
est: 17.27B (+0.1%)
|
16.07B
est: 16.82B (-4.4%)
|
19.13B
est: 20.02B (-4.4%)
|
18.87B
est: 18.82B (+0.3%)
|
19.37B
est: 19.49B (-0.6%)
|
20.18B
est: 20.17B (+0.0%)
|
21.84B
est: 21.86B (-0.1%)
|
19.20B
19.16B – 19.24B
-12.2% YoY
|
19.67B
19.47B – 20.14B
+2.5% YoY
|
20.37B
20.31B – 20.44B
+3.6% YoY
|
21.09B
20.93B – 21.38B
+3.5% YoY
|
21.88B
21.70B – 22.17B
+3.7% YoY
|
| EBITDA |
2.20B
est: 2.18B (+0.6%)
|
2.12B
est: 2.49B (-14.8%)
|
1.85B
est: 1.78B (+3.7%)
|
2.22B
est: 2.13B (+4.3%)
|
2.00B
est: 2.07B (-3.1%)
|
2.58B
est: 2.75B (-6.2%)
|
2.59B
est: 2.04B (+26.5%)
|
3.86B
est: 4.68B (-17.6%)
|
4.07B
est: 3.66B (+11.3%)
|
3.06B
est: 3.44B (-11.2%)
|
4.39B
est: 3.91B (+12.3%)
|
4.41B
est: 4.19B (+5.4%)
|
4.40B
est: 4.60B (-4.4%)
|
4.82B
est: 4.66B (+3.3%)
|
4.96B
est: 5.05B (-1.9%)
|
4.44B
4.43B – 4.45B
-12.2% YoY
|
4.55B
4.50B – 4.66B
+2.5% YoY
|
4.71B
4.70B – 4.73B
+3.6% YoY
|
4.88B
4.84B – 4.94B
+3.5% YoY
|
5.06B
5.02B – 5.13B
+3.7% YoY
|
| EBIT |
1.70B
est: 1.64B (+3.6%)
|
1.61B
est: 1.60B (+0.5%)
|
1.30B
est: 1.19B (+9.7%)
|
1.66B
est: 1.54B (+7.9%)
|
1.11B
est: 1.03B (+7.8%)
|
1.46B
est: 1.73B (-15.7%)
|
1.50B
est: 871.54M (+71.8%)
|
1.88B
est: 2.11B (-11.1%)
|
1.82B
est: 1.36B (+33.1%)
|
942.00M
est: 1.62B (-42.0%)
|
2.16B
est: 2.02B (+6.9%)
|
2.18B
est: 2.27B (-3.9%)
|
2.11B
est: 2.50B (-15.3%)
|
2.53B
est: 2.33B (+8.7%)
|
2.50B
est: 2.52B (-1.2%)
|
2.22B
2.21B – 2.22B
-12.2% YoY
|
2.27B
2.25B – 2.33B
+2.5% YoY
|
2.35B
2.35B – 2.36B
+3.6% YoY
|
2.44B
2.42B – 2.47B
+3.5% YoY
|
2.53B
2.51B – 2.56B
+3.7% YoY
|
| Net Income |
1.27B
est: 1.17B (+8.6%)
|
1.17B
est: 1.47B (-20.7%)
|
1.29B
est: 898.63M (+43.9%)
|
1.19B
est: 1.12B (+5.8%)
|
695.00M
est: 656.73M (+5.8%)
|
976.00M
est: 1.20B (-18.6%)
|
1.10B
est: 393.09M (+179.8%)
|
311.00M
est: 1.02B (-69.4%)
|
1.23B
est: 903.88M (+36.4%)
|
874.00M
est: 1.14B (-23.0%)
|
2.09B
est: 1.49B (+40.7%)
|
1.78B
est: 1.60B (+11.1%)
|
1.48B
est: 1.27B (+17.3%)
|
1.71B
est: 2.96B (-42.3%)
|
1.68B
est: 3.25B (-48.3%)
|
3.62B
3.53B – 3.71B
+11.5% YoY
|
4.05B
3.65B – 4.45B
+11.9% YoY
|
4.14B
4.08B – 4.19B
+2.1% YoY
|
4.38B
4.33B – 4.45B
+5.8% YoY
|
4.74B
4.69B – 4.82B
+8.3% YoY
|
| SGA |
1.82B
est: 1.82B (+0.1%)
|
1.92B
est: 1.90B (+1.4%)
|
2.42B
est: 2.34B (+3.3%)
|
2.15B
est: 2.10B (+2.3%)
|
2.56B
est: 2.66B (-3.6%)
|
3.01B
est: 2.77B (+8.4%)
|
2.91B
est: 2.93B (-0.7%)
|
4.02B
est: 4.25B (-5.5%)
|
4.33B
est: 4.36B (-0.5%)
|
4.19B
est: 5.50B (-23.9%)
|
4.72B
est: 4.32B (+9.3%)
|
4.71B
est: 4.57B (+3.0%)
|
4.72B
est: 5.03B (-6.2%)
|
4.86B
est: 4.93B (-1.5%)
|
5.28B
est: 5.34B (-1.2%)
|
4.69B
4.68B – 4.70B
-12.2% YoY
|
4.81B
4.76B – 4.92B
+2.5% YoY
|
4.98B
4.96B – 5.00B
+3.6% YoY
|
5.16B
5.11B – 5.23B
+3.5% YoY
|
5.35B
5.30B – 5.42B
+3.7% YoY
|
| EPS |
5.75
est: 5.09 (+13.0%)
|
5.59
est: 5.43 (+2.9%)
|
6.63
est: 5.34 (+24.2%)
|
6.13
est: 6.08 (+0.8%)
|
3.43
est: 6.93 (-50.5%)
|
4.59
est: 8.36 (-45.1%)
|
4.70
est: 9.22 (-49.0%)
|
0.62
est: 10.72 (-94.2%)
|
3.96
est: 11.39 (-65.2%)
|
2.75
est: 9.68 (-71.6%)
|
6.92
est: 12.60 (-45.1%)
|
5.93
est: 11.33 (-47.7%)
|
4.97
est: 4.39 (+13.1%)
|
5.88
est: 10.30 (-42.9%)
|
5.84
est: 11.30 (-48.3%)
|
12.58
12.28 – 12.92
+11.4% YoY
|
13.45
12.71 – 15.50
+6.9% YoY
|
14.35
14.21 – 14.61
+6.7% YoY
|
15.25
15.09 – 15.51
+6.2% YoY
|
16.51
16.34 – 16.80
+8.3% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | TD Cowen | Hold | Hold | Maintain |
| 2026-04-17 | Piper Sandler | Neutral | Neutral | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ban Siong Ang | 46.39M | 77.00% | — | — | — | — | IN | MARYLAND | 2015-02-12 | ↗ |
| 2 | FMR Corp. | 25.55M | 10.44% | 1.33M | — | 25.55M | — | HC | Delaware | 2007-04-10 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 24.18M | 8.48% | — | 458.5K | 23.02M | 1.16M | IA | Pennsylvania For | 2022-02-09 | ↗ |
| 4 | (1) BlackRock, Inc. | 21.35M | 7.50% | 18.65M | — | 21.35M | — | HC | Delaware | 2022-02-08 | ↗ |
| 5 | 52-0556948 | 20.02M | 7.00% | 7.78M | — | 20.02M | — | IA | Maryland | 2022-02-14 | ↗ |
| 6 | Edward C. Johnson 3d | 18.92M | 7.75% | — | — | 18.92M | — | IN | United States of America | 2008-07-10 | ↗ |
| 7 | STATE STREET CORPORATION | 11.41M | 4.97% | — | 11.41M | — | 11.41M | HC | BOSTON, MASSACHUSETTS | 2018-02-13 | ↗ |
| 8 | 943112180 | 7.61M | 3.16% | 5.97M | — | 7.61M | — | BK | U.S.A. | 2009-02-03 | ↗ |
| 9 | BARCLAYS GLOBAL FUND ADVISORS | 2.03M | 0.84% | 2.01M | — | 2.03M | — | IA | U.S.A. | 2009-02-03 | ↗ |
| 10 | BARCLAYS GLOBAL INVESTORS, LTD | 1.24M | 0.51% | 1.09M | — | 1.24M | — | FI | England | 2009-02-03 | ↗ |
| 11 | BARCLAYS GLOBAL INVESTORS JAPAN LIMITED | 509.4K | 0.21% | 509.4K | — | 509.4K | — | FI | Japan | 2009-02-03 | ↗ |
| 12 | BARCLAYS GLOBAL INVESTORS CANADA LIMITED | 176.9K | 0.07% | 176.9K | — | 176.9K | — | FI | Canada | 2009-02-03 | ↗ |
| 13 | BARCLAYS GLOBAL INVESTORS AUSTRALIA LIMITED | 13.1K | 0.01% | 13.1K | — | 13.1K | — | FI | Australia | 2009-02-03 | ↗ |
| 14 | 04-1867445 | — | 0.00% | — | — | — | — | BK | BOSTON, MASSACHUSETTS | 2010-02-12 | ↗ |
| 15 | BARCLAYS GLOBAL INVESTORS (DEUTSCHLAND) AG | — | 0.00% | — | — | — | — | FI | Germany | 2009-02-03 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 36.68M +4.2M (+13.0%) | 7.12B +1.0B (+17.2%) | 16.37% +5.097 pp | 0.10% +0.012 pp | USD167.14 -8.7% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 27.65M -103.6K (-0.4%) | 5.37B +171.4M (+3.3%) | 12.34% +2.701 pp | 0.09% 0.000 pp | USD214.38 -28.8% | 6 qtrs — |
| 3 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 14.38M -1.9M (-11.4%) | 2.79B -247.9M (-8.2%) | 6.42% +0.779 pp | 1.76% -0.096 pp | USD213.02 -28.4% | 14 qtrs — |
| 4 | STATE STREET CORP | 13.99M +116.7K (+0.8%) | 2.71B +118.4M (+4.6%) | 6.24% +1.425 pp | 0.09% +0.001 pp | USD157.46 -3.1% | 51 qtrs — |
| 5 | FIRST EAGLE INVESTMENT MANAGEMENT, LLC | 11.65M +1.7M (+16.5%) | 2.26B +389.5M (+20.8%) | 4.06% +0.593 pp | 3.98% +0.572 pp | USD206.28 -5.9% | 21 qtrs — |
| 6 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 9.49M +336.1K (+3.7%) | 1.84B +128.4M (+7.5%) | 3.31% +0.133 pp | 0.59% +0.063 pp | USD224.54 -13.6% | 28 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 6.89M +53.9K (+0.8%) | 1.33B +57.8M (+4.5%) | 3.07% +0.700 pp | 0.08% +0.001 pp | USD184.76 -17.4% | 78 qtrs — |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 5.30M +66.9K (+1.3%) | 1.03B +49.1M (+5.0%) | 2.36% +0.548 pp | 0.18% +0.009 pp | USD179.81 -15.2% | 81 qtrs — |
| 9 | FRANKLIN RESOURCES INC | 5.24M -1.5M (-22.2%) | 1.02B -243.2M (-19.3%) | 2.34% +0.001 pp | 0.25% -0.065 pp | USD168.07 -9.2% | 51 qtrs — |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.28M -343.3K (-7.4%) | 830.47M -34.7M (-4.0%) | 1.91% +0.304 pp | 0.09% -0.003 pp | USD217.63 -29.9% | 75 qtrs — |
| 11 | CLEARBRIDGE INVESTMENTS, LLC | 4.09M -314.7K (-7.1%) | 794.20M -30.7M (-3.7%) | 1.83% +0.296 pp | 0.64% +0.015 pp | USD211.43 -27.8% | 62 qtrs — |
| 12 | INVESCO LTD. | 3.79M +1.2M (+48.5%) | 735.62M +257.8M (+53.9%) | 1.69% +0.805 pp | 0.11% +0.038 pp | USD187.93 -18.8% | 57 qtrs — |
| 13 | NORGES BANK | 3.78M +3.8M (+100.0%) | 734.32M +734.3M (+100.0%) | 1.69% +1.688 pp | 0.08% +0.079 pp | USD152.56 +0.0% | 1 qtrs NEW |
| 14 | JPMORGAN CHASE & CO | 3.49M -1.8M (-33.9%) | 678.01M -311.7M (-31.5%) | 1.22% -0.617 pp | 0.04% -0.017 pp | USD212.17 -8.5% | 51 qtrs — |
| 15 | MORGAN STANLEY | 3.37M -92.1K (-2.7%) | 654.92M +6.0M (+0.9%) | 1.51% +0.302 pp | 0.04% 0.000 pp | USD224.54 -32.1% | 51 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.20M -102.6K (-3.1%) | 620.91M +3.4M (+0.6%) | 1.43% +0.281 pp | 0.10% -0.002 pp | USD206.08 -26.0% | 93 qtrs — |
| 17 | AMERICAN CENTURY COMPANIES INC | 3.13M -123.9K (-3.8%) | 607.37M -1.6M (-0.3%) | 1.40% +0.267 pp | 0.31% -0.005 pp | USD212.74 -28.3% | 51 qtrs — |
| 18 | VERITAS ASSET MANAGEMENT LLP | 2.87M -80.3K (-2.7%) | 557.87M +4.8M (+0.9%) | 1.28% +0.257 pp | 5.71% -0.200 pp | USD204.89 -25.5% | 24 qtrs — |
| 19 | HARRIS ASSOCIATES L P | 2.84M -273.7K (-8.8%) | 551.49M -31.6M (-5.4%) | 1.27% +0.186 pp | 0.70% -0.238 pp | USD190.11 -19.8% | 5 qtrs — |
| 20 | BANK OF AMERICA CORP /DE/ | 2.81M +114.1K (+4.2%) | 545.98M +40.8M (+8.1%) | 1.26% +0.318 pp | 0.04% +0.005 pp | USD208.82 -26.9% | 52 qtrs — |
| 21 | NORDEA INVESTMENT MANAGEMENT AB | 2.77M -458.5K (-14.2%) | 541.33M -51.6M (-8.7%) | 0.97% -0.155 pp | 0.46% -0.054 pp | USD237.50 -18.3% | 88 qtrs — |
| 22 | NORTHERN TRUST CORP | 2.50M -71.9K (-2.8%) | 486.01M +3.8M (+0.8%) | 1.12% +0.223 pp | 0.06% +0.000 pp | USD146.98 +3.8% | 51 qtrs — |
| 23 | DIMENSIONAL FUND ADVISORS LP | 2.41M +63.5K (+2.7%) | 466.86M +28.6M (+6.5%) | 1.07% +0.260 pp | 0.10% +0.004 pp | USD200.71 -24.0% | 51 qtrs — |
| 24 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2.38M -193.4K (-7.5%) | 462.90M -19.6M (-4.1%) | 1.06% +0.169 pp | 0.38% -0.016 pp | USD187.04 -18.4% | 108 qtrs — |
| 25 | LONGVIEW PARTNERS (GUERNSEY) LTD | 2.16M -110.9K (-4.9%) | 419.31M -5.8M (-1.4%) | 0.96% +0.175 pp | 4.38% -0.065 pp | USD215.19 -29.1% | 20 qtrs — |
| 26 | FIRST PACIFIC ADVISORS, LP | 1.95M +1.0M (+108.4%) | 378.68M +203.4M (+116.1%) | 0.87% +0.546 pp | 4.99% +2.563 pp | USD165.62 -7.9% | 2 qtrs — |
| 27 | LEGAL & GENERAL GROUP PLC | 1.93M +11.0K (+0.6%) | 374.64M +15.4M (+4.3%) | 0.86% +0.195 pp | 0.08% +0.003 pp | USD172.24 -11.4% | 75 qtrs — |
| 28 | BANK OF NEW YORK MELLON CORP | 1.73M -24.3K (-1.4%) | 335.25M +7.4M (+2.3%) | 0.77% +0.163 pp | 0.06% -0.004 pp | USD192.06 -20.6% | 66 qtrs — |
| 29 | GOLDMAN SACHS GROUP INC | 1.63M -216.6K (-11.8%) | 315.78M -29.3M (-8.5%) | 0.57% -0.073 pp | 0.04% -0.004 pp | USD208.60 -7.0% | 73 qtrs — |
| 30 | BARCLAYS PLC | 1.60M +939.7K (+141.9%) | 310.91M +151.2M (+94.7%) | 0.71% +0.485 pp | 0.07% +0.034 pp | USD182.26 -16.3% | 51 qtrs — |
| 31 | FMR LLC | 1.53M +528.2K (+52.6%) | 297.51M +109.4M (+58.2%) | 0.68% +0.335 pp | 0.02% +0.005 pp | USD189.09 -19.3% | 70 qtrs — |
| 32 | UBS ASSET MANAGEMENT AMERICAS INC | 1.50M -19.6K (-1.3%) | 290.46M +6.6M (+2.3%) | 0.67% +0.141 pp | 0.06% 0.000 pp | USD183.17 -16.7% | 90 qtrs — |
| 33 | MARSHALL WACE, LLP | 1.46M +1.5M (+44,008.7%) | 282.74M +282.1M (+45,634.8%) | 0.65% +0.649 pp | 0.26% +0.257 pp | USD152.62 0.0% | 13 qtrs — |
| 34 | SOUTHPOINT CAPITAL ADVISORS LP | 1.40M +— (+0.0%) | 271.70M +9.7M (+3.7%) | 0.62% +0.139 pp | 6.32% -0.557 pp | USD188.02 -18.9% | 4 qtrs — |
| 35 | AMERIPRISE FINANCIAL INC | 1.39M +1.1M (+437.5%) | 269.54M +221.1M (+457.0%) | 0.62% +0.530 pp | 0.06% +0.050 pp | USD165.42 -7.8% | 56 qtrs — |
| 36 | 1832 ASSET MANAGEMENT L.P. | 1.37M +930.5K (+213.2%) | 265.26M +183.6M (+224.8%) | 0.61% +0.458 pp | 0.20% +0.138 pp | USD167.11 -8.7% | 49 qtrs — |
| 37 | AMUNDI | 1.31M -527.4K (-28.7%) | 254.45M -98.5M (-27.9%) | 0.59% -0.053 pp | 0.07% -0.044 pp | USD230.36 -33.8% | 19 qtrs — |
| 38 | UBS GROUP AG | 1.29M +156.7K (+13.8%) | 251.00M +38.2M (+18.0%) | 0.58% +0.182 pp | 0.04% +0.007 pp | USD195.03 -21.8% | 45 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 1.25M -184.0K (-12.8%) | 243.03M -25.8M (-9.6%) | 0.56% +0.060 pp | 0.04% -0.007 pp | USD138.67 +10.0% | 57 qtrs — |
| 40 | BRANDES INVESTMENT PARTNERS, LP | 1.23M +77.1K (+6.7%) | 238.65M +22.9M (+10.6%) | 0.55% +0.149 pp | 1.82% +0.086 pp | USD169.75 -10.1% | 3 qtrs — |
| 41 | AQR CAPITAL MANAGEMENT LLC | 1.19M +153.1K (+14.8%) | 230.35M +39.7M (+20.8%) | 0.53% +0.171 pp | 0.12% -0.001 pp | USD175.71 -13.2% | 87 qtrs — |
| 42 | HOLOCENE ADVISORS, LP | 1.17M +1.2M (+100.0%) | 226.24M +226.2M (+100.0%) | 0.52% +0.520 pp | 0.48% +0.475 pp | USD152.56 +0.0% | 14 qtrs — |
| 43 | COOKE & BIELER LP | 1.13M +240.7K (+27.2%) | 218.61M +52.8M (+31.9%) | 0.50% +0.195 pp | 2.28% +0.568 pp | USD200.44 -23.9% | 52 qtrs — |
| 44 | FIDUCIARY MANAGEMENT INC /WI/ | 1.10M -86.7K (-7.3%) | 214.14M -8.6M (-3.9%) | 0.49% +0.079 pp | 2.35% +0.101 pp | USD172.39 -11.5% | 3 qtrs — |
| 45 | LONGAEVA PARTNERS L.P. | 1.00M +1.0M (+100.0%) | 194.07M +194.1M (+100.0%) | 0.45% +0.446 pp | 16.28% +16.279 pp | USD152.56 +0.0% | 1 qtrs NEW |
| 46 | DEUTSCHE BANK AG\ | 952.4K +201.3K (+26.8%) | 184.84M +44.3M (+31.5%) | 0.33% +0.072 pp | 0.06% +0.013 pp | USD216.62 -10.4% | 50 qtrs — |
| 47 | FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 951.5K +45.7K (+5.0%) | 184.65M +15.1M (+8.9%) | 0.33% +0.018 pp | 0.98% +0.065 pp | USD230.19 -15.7% | 8 qtrs — |
| 48 | ENVESTNET ASSET MANAGEMENT INC | 942.9K -132.7K (-12.3%) | 182.98M -18.3M (-9.1%) | 0.42% +0.047 pp | 0.05% -0.004 pp | USD224.06 -31.9% | 51 qtrs — |
| 49 | STARBOARD VALUE LP | 929.9K -278.1K (-23.0%) | 180.47M -45.6M (-20.2%) | 0.41% -0.005 pp | 3.42% -0.836 pp | USD210.18 -27.4% | 4 qtrs — |
| 50 | M&G PLC | 917.4K -18.1K (-1.9%) | 177.97M +3.0M (+1.7%) | 0.41% +0.085 pp | 0.91% -0.016 pp | USD193.09 -21.0% | 8 qtrs — |
| 51 | PROSHARE ADVISORS LLC | 901.8K -69.5K (-7.2%) | 175.01M -6.8M (-3.7%) | 0.31% -0.023 pp | 0.31% -0.072 pp | USD214.96 -9.7% | 76 qtrs — |
| 52 | COLONY GROUP, LLC | 884.1K +831.0K (+1,566.6%) | 171.53M +161.6M (+1,635.7%) | 0.39% +0.376 pp | 0.20% +0.180 pp | USD155.74 -2.0% | 9 qtrs — |
| 53 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 839.9K +469.8K (+127.0%) | 162.99M +93.7M (+135.4%) | 0.37% +0.246 pp | 0.10% +0.052 pp | USD161.79 -5.7% | 3 qtrs — |
| 54 | SWISS NATIONAL BANK | 785.5K -40.7K (-4.9%) | 152.44M -2.2M (-1.4%) | 0.35% +0.064 pp | 0.09% +0.001 pp | USD168.02 -9.2% | 51 qtrs — |
| 55 | RAYMOND JAMES FINANCIAL INC | 765.4K -171.0K (-18.3%) | 148.54M -26.7M (-15.2%) | 0.34% +0.016 pp | 0.05% -0.010 pp | USD222.78 -31.5% | 5 qtrs — |
| 56 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 735.9K -147.3K (-16.7%) | 142.81M -22.5M (-13.6%) | 0.33% +0.022 pp | 0.08% -0.017 pp | USD218.38 -30.1% | 57 qtrs — |
| 57 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 730.6K +334.8K (+84.6%) | 141.78M +67.7M (+91.4%) | 0.33% +0.189 pp | 0.24% +0.107 pp | USD170.75 -10.7% | 4 qtrs — |
| 58 | SG AMERICAS SECURITIES, LLC | 730.1K +491.3K (+205.7%) | 141.68M +97.0M (+217.0%) | 0.25% +0.172 pp | 0.18% +0.030 pp | USD189.34 +2.5% | 51 qtrs — |
| 59 | CULLEN CAPITAL MANAGEMENT, LLC | 697.8K -18.5K (-2.6%) | 135.42M +1.4M (+1.0%) | 0.31% +0.063 pp | 1.48% +0.012 pp | USD174.29 -12.5% | 3 qtrs — |
| 60 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 665.5K -30.5K (-4.4%) | 129.15M -1.1M (-0.9%) | 0.23% -0.010 pp | 0.08% +0.001 pp | USD158.28 +22.6% | 59 qtrs — |
| 61 | ROYAL BANK OF CANADA | 644.1K -20.6K (-3.1%) | 125.01M +595.0K (+0.5%) | 0.29% +0.057 pp | 0.02% 0.000 pp | USD223.91 -31.9% | 51 qtrs — |
| 62 | NUVEEN, LLC | 632.5K +27.9K (+4.6%) | 122.74M +9.6M (+8.5%) | 0.28% +0.072 pp | 0.03% +0.002 pp | USD210.05 -27.4% | 4 qtrs — |
| 63 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 627.9K +26.7K (+4.4%) | 122.40M +9.9M (+8.8%) | 0.22% +0.010 pp | 0.08% +0.002 pp | USD227.12 -14.6% | 58 qtrs — |
| 64 | DAVENPORT & CO LLC | 614.0K -30.7K (-4.8%) | 119.45M -621.7K (-0.5%) | 0.21% -0.010 pp | 0.64% -0.004 pp | USD218.15 -11.0% | 51 qtrs — |
| 65 | DEKABANK DEUTSCHE GIROZENTRALE | 460.1K +— (+0.0%) | 117.86M +33.6M (+39.9%) | 0.21% +0.046 pp | 0.20% +0.062 pp | USD203.70 -25.1% | 66 qtrs — |
| 66 | NOMURA ASSET MANAGEMENT CO LTD | 581.0K -16.1K (-2.7%) | 112.76M +994.1K (+0.9%) | 0.26% +0.052 pp | 0.29% -0.006 pp | USD217.54 -29.9% | 76 qtrs — |
| 67 | BRISTOL JOHN W & CO INC /NY/ | 577.5K -11.9K (-2.0%) | 112.08M +1.8M (+1.6%) | 0.26% +0.053 pp | 1.72% -0.018 pp | USD157.70 -3.3% | 80 qtrs — |
| 68 | BNP PARIBAS ARBITRAGE, SNC | 575.4K +269.8K (+88.3%) | 111.66M +54.5M (+95.2%) | 0.26% +0.151 pp | 0.05% +0.020 pp | USD179.35 -14.9% | 51 qtrs — |
| 69 | EVERETT HARRIS & CO /CA/ | 550.9K +1.4K (+0.3%) | 106.91M +4.1M (+4.0%) | 0.25% +0.055 pp | 1.29% +0.025 pp | USD143.52 +6.3% | 61 qtrs — |
| 70 | LIONTRUST INVESTMENT PARTNERS LLP | 547.1K -47.9K (-8.1%) | 106.17M -5.2M (-4.7%) | 0.24% +0.038 pp | 1.58% +0.010 pp | USD207.98 -26.6% | 4 qtrs — |
| 71 | NEW YORK STATE COMMON RETIREMENT FUND | 545.5K -1.1K (-0.2%) | 105.87M +3.6M (+3.5%) | 0.24% +0.054 pp | 0.14% +0.009 pp | USD166.92 -8.6% | 103 qtrs — |
| 72 | MAWER INVESTMENT MANAGEMENT LTD. | 543.1K -522.9K (-49.0%) | 105.41M -94.1M (-47.2%) | 0.24% -0.128 pp | 0.59% -0.446 pp | USD177.47 -14.0% | 51 qtrs — |
| 73 | BANK OF MONTREAL /CAN/ | 536.2K +141.3K (+35.8%) | 104.07M +30.1M (+40.8%) | 0.24% +0.102 pp | 0.04% +0.008 pp | USD200.89 -24.1% | 46 qtrs — |
| 74 | CITADEL ADVISORS LLC | 512.8K +154.2K (+43.0%) | 99.52M +32.4M (+48.3%) | 0.23% +0.104 pp | 0.01% +0.005 pp | USD195.35 -21.9% | 52 qtrs — |
| 75 | ABRDN PLC | 511.5K -4.6K (-0.9%) | 99.26M +4.3M (+4.5%) | 0.18% -0.001 pp | 0.15% +0.004 pp | USD219.50 -11.6% | 34 qtrs — |
| 76 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 508.2K +— (+0.0%) | 98.64M +3.5M (+3.7%) | 0.23% +0.050 pp | 0.08% -0.002 pp | USD163.73 -6.8% | 91 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 485.7K -10.9K (-2.2%) | 94.26M +1.3M (+1.4%) | 0.22% +0.044 pp | 0.09% -0.001 pp | USD147.07 +3.7% | 52 qtrs — |
| 78 | RHUMBLINE ADVISERS | 470.7K -5.1K (-1.1%) | 91.35M +2.3M (+2.6%) | 0.21% +0.045 pp | 0.07% +0.002 pp | USD163.49 -6.7% | 52 qtrs — |
| 79 | NATIONAL PENSION SERVICE | 463.0K +18.3K (+4.1%) | 89.86M +6.6M (+8.0%) | 0.21% +0.052 pp | 0.07% +0.002 pp | USD200.30 -23.8% | 46 qtrs — |
| 80 | RIVER ROAD ASSET MANAGEMENT, LLC | 436.9K +45.9K (+11.7%) | 84.78M +11.6M (+15.9%) | 0.15% +0.017 pp | 0.93% +0.110 pp | USD200.41 -3.2% | 5 qtrs — |
| 81 | JANUS HENDERSON GROUP PLC | 421.2K +7.7K (+1.9%) | 81.75M +4.3M (+5.6%) | 0.19% +0.044 pp | 0.04% +0.001 pp | USD182.92 -16.6% | 87 qtrs — |
| 82 | LAZARD FRERES GESTION S.A.S. | 375.6K -86.2K (-18.7%) | 72.88M -13.6M (-15.7%) | 0.17% +0.007 pp | 1.31% -0.332 pp | USD238.36 -36.0% | 21 qtrs — |
| 83 | CITIGROUP INC | 368.7K +9.1K (+2.5%) | 71.55M +4.2M (+6.3%) | 0.16% +0.040 pp | 0.03% +0.002 pp | USD212.32 -28.1% | 108 qtrs — |
| 84 | STIFEL FINANCIAL CORP | 367.0K -60.1K (-14.1%) | 71.23M -8.7M (-10.9%) | 0.16% +0.016 pp | 0.06% -0.009 pp | USD211.00 -27.7% | 48 qtrs — |
| 85 | CLARKSTON CAPITAL PARTNERS, LLC | 366.3K -10.6K (-2.8%) | 71.08M +545.9K (+0.8%) | 0.16% +0.033 pp | 1.65% +0.126 pp | USD181.34 -15.9% | 5 qtrs — |
| 86 | LPL FINANCIAL LLC | 363.1K -33.3K (-8.4%) | 70.46M -3.7M (-5.0%) | 0.16% +0.024 pp | 0.02% -0.002 pp | USD219.02 -30.3% | 51 qtrs — |
| 87 | NATIXIS ADVISORS, L.P. | 356.2K +48.7K (+15.8%) | 69.14M +11.6M (+20.1%) | 0.16% +0.052 pp | 0.10% +0.014 pp | USD194.15 -21.4% | 38 qtrs — |
| 88 | HSBC HOLDINGS PLC | 350.0K +350.0K (+100.0%) | 68.35M +68.4M (+100.0%) | 0.12% +0.122 pp | 0.03% +0.035 pp | USD194.07 +0.0% | 1 qtrs NEW |
| 89 | FREESTONE GROVE PARTNERS LP | 335.4K +335.4K (+100.0%) | 65.09M +65.1M (+100.0%) | 0.15% +0.150 pp | 0.47% +0.471 pp | USD152.56 +0.0% | 1 qtrs NEW |
| 90 | ALLIANCEBERNSTEIN L.P. | 307.7K -506.0K (-62.2%) | 59.72M -92.6M (-60.8%) | 0.14% -0.145 pp | 0.02% -0.029 pp | USD222.04 -31.3% | 61 qtrs — |
| 91 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 305.5K +112.7K (+58.5%) | 59.29M +23.2M (+64.3%) | 0.14% +0.069 pp | 0.01% +0.003 pp | USD179.29 -14.9% | 51 qtrs — |
| 92 | BALYASNY ASSET MANAGEMENT L.P. | 283.6K +283.6K (+100.0%) | 55.04M +55.0M (+100.0%) | 0.13% +0.127 pp | 0.07% +0.070 pp | USD152.56 +0.0% | 13 qtrs — |
| 93 | FIRST TRUST ADVISORS LP | 278.6K -18.1K (-6.1%) | 54.07M -1.5M (-2.6%) | 0.12% +0.021 pp | 0.04% -0.002 pp | USD221.88 -31.2% | 51 qtrs — |
| 94 | — | 269.5K +269.5K (+100.0%) | 52.30M +52.3M (+100.0%) | 0.12% +0.120 pp | 1.03% +1.027 pp | USD152.56 +0.0% | 1 qtrs NEW |
| 95 | TD ASSET MANAGEMENT INC | 267.5K -11.2K (-4.0%) | 51.91M -245.4K (-0.5%) | 0.12% +0.023 pp | 0.04% -0.001 pp | USD199.84 -23.7% | 51 qtrs — |
| 96 | SEI INVESTMENTS CO | 267.1K +78.9K (+41.9%) | 51.83M +16.6M (+47.1%) | 0.12% +0.054 pp | 0.05% +0.013 pp | USD197.79 -22.9% | 45 qtrs — |
| 97 | BELLEVUE GROUP AG | 265.7K -31.2K (-10.5%) | 51.56M -4.0M (-7.2%) | 0.12% +0.015 pp | 0.98% -0.178 pp | USD227.46 -32.9% | 40 qtrs — |
| 98 | NEUBERGER BERMAN GROUP LLC | 262.5K -10.1K (-3.7%) | 50.98M +40.0K (+0.1%) | 0.12% +0.023 pp | 0.04% +0.001 pp | USD228.63 -33.3% | 57 qtrs — |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Feld Michael | Officer | S-Sale | D | Common Stock | 74 | 151.94 | 11.2K | 21,159 | D | ↗ |
| 2026-04-06 | Neal Shana Carol | Officer | F-InKind | D | Common Stock | 1,146 | 0.00 | — | 23,966 | D | ↗ |
| 2026-03-26 | Feld Michael | Officer | S-Sale | D | Common Stock | 75 | 156.83 | 11.8K | 21,233 | D | ↗ |
| 2026-03-16 | Minnix Lanesha | Officer | A-Award | A | Common Stock | 7,492 | 0.00 | — | 7,492 | D | ↗ |
| 2026-03-02 | Spikner Pamela L. | Officer | A-Award | A | Common Stock | 931 | 0.00 | — | 3,323 | D | ↗ |
| 2026-03-02 | Roque Vitor | Officer | A-Award | A | Common Stock | 931 | 0.00 | — | 6,510 | D | ↗ |
| 2026-02-26 | Feld Michael | Officer | S-Sale | D | Common Stock | 75 | 181.84 | 13.6K | 21,308 | D | ↗ |
| 2026-02-18 | SCOTT BERTRAM L | Director | S-Sale | D | Common Stock | 953 | 182.61 | 174.0K | 36,763 | D | ↗ |
| 2026-02-04 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 272 | 0.00 | — | 11,649 | D | ↗ |
| 2026-02-04 | Huffines Robert Luther | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 100 | 0.00 | — | 100 | D | ↗ |
| 2026-02-04 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 30 | 0.00 | — | 1,714 | D | ↗ |
| 2026-02-01 | Urbini Massimiliano | Officer | — | — | Common Stock | 0 | 0.00 | — | 4,133 | D | ↗ |
| 2026-01-27 | Wright Jacqueline | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 1,279 | D | ↗ |
| 2026-01-27 | Waldstreicher Joanne | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 3,391 | D | ↗ |
| 2026-01-27 | SCOTT BERTRAM L | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 37,716 | D | ↗ |
| 2026-01-27 | RING TIMOTHY M | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 59,160 | D | ↗ |
| 2026-01-27 | Jones Christopher Ian Montague | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 24,304 | D | ↗ |
| 2026-01-27 | Huffines Robert Luther | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 1,279 | D | ↗ |
| 2026-01-27 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 9,143 | D | ↗ |
| 2026-01-27 | HAYES GREGORY | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 7,159 | D | ↗ |
| 2026-01-27 | ECKERT R ANDREW | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 10,423 | D | ↗ |
| 2026-01-27 | Byington Carrie L | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 5,018 | D | ↗ |
| 2026-01-27 | Brown William M | Director | A-Award | A | Common Stock | 1,098 | 0.00 | — | 4,663 | D | ↗ |
| 2026-01-26 | Feld Michael | Officer | S-Sale | D | Common Stock | 75 | 202.73 | 15.2K | 16,431 | D | ↗ |
| 2026-01-21 | Spikner Pamela L. | Officer | F-InKind | D | Common Stock | 84 | 0.00 | — | 1,832 | D | ↗ |
| 2026-01-15 | Garrison Michael David | Officer | D-Return | D | Common Stock | 2,454 | 209.00 | 512.9K | 13,705 | D | ↗ |
| 2026-01-03 | Shan David | Officer | F-InKind | D | Common Stock | 44 | 0.00 | — | 8,926 | D | ↗ |
| 2025-12-26 | Feld Michael | Officer | S-Sale | D | Common Stock | 74 | 196.08 | 14.5K | 16,506 | D | ↗ |
| 2025-12-17 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 629 | 196.03 | 123.3K | 13,105 | D | ↗ |
| 2025-12-05 | Roque Vitor | Officer | — | — | Common Stock | 0 | 0.00 | — | 4,477 | D | ↗ |
| 2025-12-01 | Wright Jacqueline | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-12-01 | Huffines Robert Luther | Director | A-Award | A | Common Stock | 180 | 0.00 | — | 180 | D | ↗ |
| 2025-12-01 | Feld Michael | Officer | S-Sale | D | Common Stock | 75 | 193.36 | 14.5K | 16,580 | D | ↗ |
| 2025-11-26 | Urbini Massimiliano | Officer | — | — | Stock Appreciation Rights | 1,984 | 224.25 | 444.9K | 0 | D | ↗ |
| 2025-11-26 | Spikner Pamela L. | Officer | A-Award | A | Common Stock | 1,234 | 0.00 | — | 1,916 | D | ↗ |
| 2025-11-26 | Shan David | Officer | A-Award | A | Common Stock | 3,504 | 0.00 | — | 8,079 | D | ↗ |
| 2025-11-26 | Roque Vitor | Officer | — | — | Stock Appreciation Rights | 1,849 | 224.25 | 414.6K | 0 | D | ↗ |
| 2025-11-26 | Polen Thomas E Jr | Officer | A-Award | A | Stock Appreciation Rights | 165,581 | 193.90 | 32.11M | 165,581 | D | ↗ |
| 2025-11-26 | Neal Shana Carol | Officer | A-Award | A | Common Stock | 6,727 | 0.00 | — | 20,255 | D | ↗ |
| 2025-11-26 | Muhsin Bilal | Officer | A-Award | A | Common Stock | 9,530 | 0.00 | — | 21,751 | D | ↗ |
| 2025-11-26 | Mocherla Pavan Kumar | Officer | A-Award | A | Common Stock | 2,208 | 0.00 | — | 5,055 | D | ↗ |
| 2025-11-26 | Goette Roland | Officer | A-Award | A | Common Stock | 1,906 | 0.00 | — | 16,123 | D | ↗ |
| 2025-11-26 | Garrison Michael David | Officer | A-Award | A | Common Stock | 3,048 | 0.00 | — | 15,503 | D | ↗ |
| 2025-11-26 | Feld Michael | Officer | A-Award | A | Common Stock | 8,829 | 0.00 | — | 17,074 | D | ↗ |
| 2025-11-26 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 4,245 | 0.00 | — | 22,982 | D | ↗ |
| 2025-11-26 | Byrd Richard | Officer | A-Award | A | Common Stock | 2,385 | 0.00 | — | 15,568 | D | ↗ |
| 2025-11-07 | SCOTT BERTRAM L | Director | S-Sale | D | Common Stock | 217 | 176.58 | 38.3K | 35,816 | D | ↗ |
| 2025-11-04 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 168 | 0.00 | — | 11,316 | D | ↗ |
| 2025-11-04 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 34 | 0.00 | — | 1,675 | D | ↗ |
| 2025-10-27 | Feld Michael | Officer | S-Sale | D | Common Stock | 57 | 186.01 | 10.6K | 8,245 | D | ↗ |
| 2025-09-26 | Feld Michael | Officer | S-Sale | D | Common Stock | 58 | 181.03 | 10.5K | 8,302 | D | ↗ |
| 2025-09-10 | Fraser Claire | Director | S-Sale | D | Common Stock | 917 | 187.50 | 171.9K | 22,226 | D | ↗ |
| 2025-09-01 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 278 | 0.00 | — | 21,221 | D | ↗ |
| 2025-09-01 | Byrd Richard | Officer | F-InKind | D | Common Stock | 216 | 0.00 | — | 6,736 | D | ↗ |
| 2025-08-22 | Feld Michael | Officer | S-Sale | D | Common Stock | 57 | 197.99 | 11.3K | 8,360 | D | ↗ |
| 2025-08-20 | Feld Michael | Officer | F-InKind | D | Common Stock | 773 | 0.00 | — | 8,417 | D | ↗ |
| 2025-08-11 | HAYES GREGORY | Director | P-Purchase | A | Common Stock | 5,250 | 191.57 | 1.01M | 6,046 | D | ↗ |
| 2025-08-08 | Fraser Claire | Director | S-Sale | D | Common Stock | 863 | 192.30 | 166.0K | 23,143 | D | ↗ |
| 2025-08-07 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 168 | 0.00 | — | 11,089 | D | ↗ |
| 2025-08-07 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 34 | 0.00 | — | 1,632 | D | ↗ |
| 2025-07-18 | Garrison Michael David | Officer | M-Exempt | D | Stock Appreciation Rights | 6,360 | 147.68 | 939.2K | 0 | D | ↗ |
| 2025-07-02 | Muhsin Bilal | Officer | A-Award | A | Common Stock | 12,221 | 0.00 | — | 12,221 | D | ↗ |
| 2025-06-02 | Shan David | Officer | S-Sale | D | Common Stock | 1,166 | 171.19 | 199.6K | 4,575 | D | ↗ |
| 2025-05-06 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 145 | 0.00 | — | 10,855 | D | ↗ |
| 2025-05-06 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 29 | 0.00 | — | 1,588 | D | ↗ |
| 2025-04-09 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 479 | 197.28 | 94.5K | 4,887 | D | ↗ |
| 2025-04-04 | Neal Shana Carol | Officer | F-InKind | D | Common Stock | 1,886 | 0.00 | — | 13,528 | D | ↗ |
| 2025-03-26 | HAYES GREGORY | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-03-18 | Byrd Richard | Officer | S-Sale | D | Common Stock | 459 | 230.00 | 105.6K | 6,952 | D | ↗ |
| 2025-03-12 | Byrd Richard | Officer | S-Sale | D | Common Stock | 1,940 | 224.91 | 436.3K | 7,411 | D | ↗ |
| 2025-03-01 | Garrison Michael David | Officer | F-InKind | D | Common Stock | 178 | 0.00 | — | 5,366 | D | ↗ |
| 2025-02-12 | SCOTT BERTRAM L | Director | S-Sale | D | Common Stock | 700 | 227.99 | 159.6K | 36,033 | D | ↗ |
| 2025-02-10 | Henderson Jeffrey William | Director | P-Purchase | A | Common Stock | 1,500 | 233.62 | 350.4K | 8,015 | D | ↗ |
| 2025-02-06 | Spikner Pamela L. | Officer | — | — | Common Stock | 0 | 0.00 | — | 682 | D | ↗ |
| 2025-02-06 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 222 | 0.00 | — | 10,662 | D | ↗ |
| 2025-02-06 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 121 | 0.00 | — | 1,552 | D | ↗ |
| 2025-01-28 | Waldstreicher Joanne | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 2,270 | D | ↗ |
| 2025-01-28 | SCOTT BERTRAM L | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 36,733 | D | ↗ |
| 2025-01-28 | RING TIMOTHY M | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 57,915 | D | ↗ |
| 2025-01-28 | Jones Christopher Ian Montague | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 22,701 | D | ↗ |
| 2025-01-28 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 6,515 | D | ↗ |
| 2025-01-28 | Fraser Claire | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 24,006 | D | ↗ |
| 2025-01-28 | ECKERT R ANDREW | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 9,170 | D | ↗ |
| 2025-01-28 | Byington Carrie L | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 3,834 | D | ↗ |
| 2025-01-28 | Brown William M | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 3,486 | D | ↗ |
| 2025-01-28 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 930 | 0.00 | — | 14,264 | D | ↗ |
| 2025-01-21 | Shan David | Officer | S-Sale | D | Common Stock | 500 | 240.00 | 120.0K | 5,741 | D | ↗ |
| 2025-01-21 | Neal Shana Carol | Officer | S-Sale | D | Common Stock | 787 | 240.00 | 188.9K | 15,414 | D | ↗ |
| 2025-01-17 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 597 | 236.51 | 141.2K | 5,544 | D | ↗ |
| 2025-01-07 | Neal Shana Carol | Officer | S-Sale | D | Common Stock | 788 | 235.00 | 185.2K | 16,201 | D | ↗ |
| 2025-01-03 | Shan David | Officer | F-InKind | D | Common Stock | 44 | 0.00 | — | 6,241 | D | ↗ |
| 2024-12-19 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 2,838 | 223.33 | 633.8K | 6,141 | D | ↗ |
| 2024-12-09 | Goette Roland | Officer | S-Sale | D | Common Stock | 638 | 219.03 | 139.7K | 14,217 | D | ↗ |
| 2024-12-06 | Neal Shana Carol | Officer | S-Sale | D | Common Stock | 1,000 | 220.49 | 220.5K | 16,989 | D | ↗ |
| 2024-12-06 | Goette Roland | Officer | M-Exempt | D | Stock Appreciation Rights | 6,339 | 167.91 | 1.06M | 0 | D | ↗ |
| 2024-12-05 | Shan David | Officer | S-Sale | D | Common Stock | 1,500 | 220.25 | 330.4K | 6,285 | D | ↗ |
| 2024-11-26 | Urbini Massimiliano | Officer | — | — | Stock Appreciation Rights | 1,843 | 238.89 | 440.3K | 0 | D | ↗ |
| 2024-11-26 | Shan David | Officer | A-Award | A | Common Stock | 1,106 | 0.00 | — | 7,909 | D | ↗ |
| 2024-11-26 | Roque Vitor | Officer | — | — | Stock Appreciation Rights | 1,843 | 238.89 | 440.3K | 0 | D | ↗ |
| 2024-11-26 | Quinn Michelle | Officer | F-InKind | D | Common Stock | 376 | 0.00 | — | 6,927 | D | ↗ |
| 2024-11-26 | Polen Thomas E Jr | Officer | A-Award | A | Common Stock | 36,585 | 0.00 | — | 123,935 | D | ↗ |
| 2024-11-26 | Neal Shana Carol | Officer | A-Award | A | Common Stock | 2,109 | 0.00 | — | 18,498 | D | ↗ |
| 2024-11-26 | Mocherla Pavan Kumar | Officer | A-Award | A | Common Stock | 180 | 0.00 | — | 2,872 | D | ↗ |
| 2024-11-26 | Goette Roland | Officer | A-Award | A | Common Stock | 2,161 | 0.00 | — | 15,690 | D | ↗ |
| 2024-11-26 | Garrison Michael David | Officer | F-InKind | D | Common Stock | 1,230 | 0.00 | — | 8,979 | D | ↗ |
| 2024-11-26 | Feld Michael | Officer | A-Award | A | Common Stock | 2,553 | 0.00 | — | 9,190 | D | ↗ |
| 2024-11-26 | Ezell Antoine C | Officer | A-Award | A | Stock Appreciation Rights | 5,437 | 224.25 | 1.22M | 5,437 | D | ↗ |
| 2024-11-26 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 5,192 | 0.00 | — | 21,499 | D | ↗ |
| 2024-11-26 | Byrd Richard | Officer | A-Award | A | Common Stock | 2,275 | 0.00 | — | 10,555 | D | ↗ |
| 2024-11-21 | Neal Shana Carol | Officer | F-InKind | D | Common Stock | 32 | 0.00 | — | 16,989 | D | ↗ |
| 2024-11-05 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 128 | 0.00 | — | 10,392 | D | ↗ |
| 2024-11-05 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 128 | 0.00 | — | 1,424 | D | ↗ |
| 2024-09-07 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 466 | 0.00 | — | 12,792 | — | ↗ |
| 2024-09-01 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 254 | 0.00 | — | 13,258 | — | ↗ |
| 2024-09-01 | Byrd Richard | Officer | F-InKind | D | Common Stock | 216 | 0.00 | — | 6,060 | — | ↗ |
| 2024-08-20 | Feld Michael | Officer | — | D | Common Stock | 0 | 0.00 | — | 3 | — | ↗ |
| 2024-08-14 | Goette Roland | Officer | M-Exempt | A | Common Stock | 5,295 | 132.54 | 701.8K | 16,603 | — | ↗ |
| 2024-07-31 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 124 | 0.00 | — | 10,224 | — | ↗ |
| 2024-07-31 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 124 | 0.00 | — | 1,291 | — | ↗ |
| 2024-07-01 | Spoerel Thomas J | Officer | F-InKind | D | Common Stock | 48 | 0.00 | — | 1,928 | — | ↗ |
| 2024-06-10 | Spoerel Thomas J | Officer | S-Sale | D | Common Stock | 300 | 239.31 | 71.8K | 1,976 | — | ↗ |
| 2024-05-15 | Goette Roland | Officer | S-Sale | D | Common Stock | 800 | 235.29 | 188.2K | 13,808 | — | ↗ |
| 2024-05-13 | Goette Roland | Officer | S-Sale | D | Common Stock | 28 | 237.90 | 6.7K | 14,608 | — | ↗ |
| 2024-05-03 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 129 | 0.00 | — | 9,954 | — | ↗ |
| 2024-05-03 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 129 | 0.00 | — | 1,162 | — | ↗ |
| 2024-04-30 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 1,715 | 232.81 | 399.3K | 5,381 | — | ↗ |
| 2024-04-04 | Neal Shana Carol | Officer | F-InKind | D | Common Stock | 1,921 | 0.00 | — | 16,389 | — | ↗ |
| 2024-03-14 | Spoerel Thomas J | Officer | S-Sale | D | Common Stock | 282 | 238.29 | 67.2K | 2,276 | — | ↗ |
| 2024-03-01 | Spoerel Thomas J | Officer | F-InKind | D | Common Stock | 36 | 0.00 | — | 2,558 | — | ↗ |
| 2024-03-01 | Garrison Michael David | Officer | F-InKind | D | Common Stock | 178 | 0.00 | — | 7,096 | — | ↗ |
| 2024-03-01 | Ezell Antoine C | Officer | F-InKind | D | Common Stock | 282 | 0.00 | — | 9,320 | — | ↗ |
| 2024-02-05 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 126 | 0.00 | — | 9,787 | — | ↗ |
| 2024-02-05 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 126 | 0.00 | — | 1,029 | — | ↗ |
| 2024-01-23 | Waldstreicher Joanne | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 1,323 | — | ↗ |
| 2024-01-23 | SCOTT BERTRAM L | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 35,197 | — | ↗ |
| 2024-01-23 | RING TIMOTHY M | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 56,890 | — | ↗ |
| 2024-01-23 | Jones Christopher Ian Montague | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 21,405 | — | ↗ |
| 2024-01-23 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 5,568 | — | ↗ |
| 2024-01-23 | Fraser Claire | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 22,696 | — | ↗ |
| 2024-01-23 | ECKERT R ANDREW | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 8,124 | — | ↗ |
| 2024-01-23 | Byington Carrie L | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 2,855 | — | ↗ |
| 2024-01-23 | Brown William M | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 2,512 | — | ↗ |
| 2024-01-23 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 900 | 0.00 | — | 13,242 | — | ↗ |
| 2024-01-03 | Shan David | Officer | F-InKind | D | Common Stock | 44 | 0.00 | — | 5,693 | — | ↗ |
| 2023-12-11 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 1,239 | 232.46 | 288.0K | 7,274 | — | ↗ |
| 2023-11-28 | Byrd Richard | Officer | S-Sale | D | Common Stock | 2,156 | 238.47 | 514.1K | 4,120 | — | ↗ |
| 2023-11-26 | Urbini Massimiliano | Officer | — | — | Stock Appreciation Rights | 2,378 | 238.06 | 566.1K | 0 | D | ↗ |
| 2023-11-26 | Spoerel Thomas J | Officer | A-Award | A | Common Stock | 757 | 0.00 | — | 2,959 | — | ↗ |
| 2023-11-26 | Shan David | Officer | — | D | Stock Apprciation Rights | 5,305 | 238.06 | 1.26M | 0 | — | ↗ |
| 2023-11-26 | Roque Vitor | Officer | — | — | Stock Appreciation Rights | 2,195 | 238.06 | 522.5K | 0 | D | ↗ |
| 2023-11-26 | Quinn Michelle | Officer | A-Award | A | Common Stock | 909 | 0.00 | — | 5,395 | — | ↗ |
| 2023-11-26 | Polen Thomas E Jr | Officer | A-Award | A | Rights to Common Stock Under Deferred Compensation Plan | 7,520 | 238.89 | 1.80M | 70,855 | — | ↗ |
| 2023-11-26 | Neal Shana Carol | Officer | A-Award | A | Common Stock | 1,659 | 0.00 | — | 18,568 | — | ↗ |
| 2023-11-26 | Mocherla Pavan Kumar | Officer | A-Award | A | Stock Appreciation Rights | 2,764 | 238.89 | 660.3K | 2,764 | — | ↗ |
| 2023-11-26 | Hickey David | Officer | A-Award | A | Rights to Common Stock Under Deferred Compensation Plan | 3,024 | 238.89 | 722.4K | 12,237 | — | ↗ |
| 2023-11-26 | Goette Roland | Officer | A-Award | A | Common Stock | 2,608 | 0.00 | — | 18,603 | — | ↗ |
| 2023-11-26 | Garrison Michael David | Officer | F-InKind | D | Common Stock | 1,646 | 0.00 | — | 8,513 | — | ↗ |
| 2023-11-26 | Ezell Antoine C | Officer | A-Award | A | Stock Appreciation Rights | 5,298 | 238.89 | 1.27M | 5,298 | — | ↗ |
| 2023-11-26 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 812 | 0.00 | — | 13,512 | — | ↗ |
| 2023-11-26 | Byrd Richard | Officer | A-Award | A | Stock Appreciation Rights | 8,061 | 238.89 | 1.93M | 8,061 | — | ↗ |
| 2023-11-20 | Neal Shana Carol | Officer | M-Exempt | D | Rights to Common Stock Under Deferred Compensation Plan | 110 | 0.00 | — | 448 | D | ↗ |
| 2023-11-16 | Goette Roland | Officer | M-Exempt | A | Common Stock | 3,544 | 107.12 | 379.6K | 17,164 | — | ↗ |
| 2023-11-03 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 118 | 0.00 | — | 9,624 | — | ↗ |
| 2023-11-03 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 118 | 0.00 | — | 910 | — | ↗ |
| 2023-09-07 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 601 | 0.00 | — | 10,999 | — | ↗ |
| 2023-09-05 | Byrd Richard | Officer | S-Sale | D | Common Stock | 459 | 274.48 | 126.0K | 3,444 | — | ↗ |
| 2023-09-01 | DelOrefice Christopher | Officer | F-InKind | D | Common Stock | 353 | 0.00 | — | 11,600 | — | ↗ |
| 2023-09-01 | Byrd Richard | Officer | F-InKind | D | Common Stock | 216 | 0.00 | — | 3,903 | — | ↗ |
| 2023-08-28 | Fraser Claire | Director | S-Sale | D | Common Stock | 848 | 281.66 | 238.8K | 21,608 | — | ↗ |
| 2023-08-11 | Hickey David | Officer | S-Sale | D | Common Stock | 2,974 | 277.85 | 826.3K | 4,199 | — | ↗ |
| 2023-08-08 | Garrison Michael David | Officer | S-Sale | D | Common Stock | 1,300 | 277.13 | 360.3K | 5,157 | — | ↗ |
| 2023-08-02 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 108 | 0.00 | — | 9,441 | — | ↗ |
| 2023-08-02 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 108 | 0.00 | — | 785 | — | ↗ |
| 2023-07-24 | Waldstreicher Joanne | Director | A-Award | A | Common Stock | 419 | 0.00 | — | 419 | — | ↗ |
| 2023-07-01 | Spoerel Thomas J | Officer | A-Award | D | Common Stock | 47 | 0.00 | — | 1,827 | — | ↗ |
| 2023-05-05 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 118 | 0.00 | — | 9,270 | — | ↗ |
| 2023-05-05 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 118 | 0.00 | — | 671 | — | ↗ |
| 2023-05-01 | Quinn Michelle | Officer | F-InKind | D | Common Stock | 99 | 0.00 | — | 3,280 | — | ↗ |
| 2023-04-04 | Neal Shana Carol | Officer | F-InKind | D | Common Stock | 731 | 0.00 | — | 8,680 | — | ↗ |
| 2023-03-02 | Ezell Antoine C | Officer | F-InKind | D | Common Stock | 650 | 0.00 | — | 7,187 | — | ↗ |
| 2023-03-01 | Spoerel Thomas J | Officer | F-InKind | D | Common Stock | 35 | 0.00 | — | 1,874 | — | ↗ |
| 2023-03-01 | Garrison Michael David | Officer | F-InKind | D | Common Stock | 193 | 0.00 | — | 6,457 | — | ↗ |
| 2023-03-01 | Ezell Antoine C | Officer | F-InKind | D | Common Stock | 418 | 0.00 | — | 7,837 | — | ↗ |
| 2023-02-03 | Quinn Michelle | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,379 | — | ↗ |
| 2023-02-03 | Byrd Richard | Officer | S-Sale | D | Common Stock | 1,421 | 248.60 | 353.3K | 4,119 | — | ↗ |
| 2023-02-02 | Jones Christopher Ian Montague | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 205 | 0.00 | — | 9,086 | — | ↗ |
| 2023-02-02 | Byington Carrie L | Director | A-Award | A | Rights to Common Stock Under BD Deferred Compensation Plan | 106 | 0.00 | — | 548 | — | ↗ |
| 2023-01-26 | Fraser Claire | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 22,311 | — | ↗ |
| 2023-01-24 | SCOTT BERTRAM L | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 33,779 | — | ↗ |
| 2023-01-24 | RING TIMOTHY M | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 78,830 | — | ↗ |
| 2023-01-24 | LARSEN MARSHALL O | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 28,919 | — | ↗ |
| 2023-01-24 | Jones Christopher Ian Montague | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 29,171 | — | ↗ |
| 2023-01-24 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 4,653 | — | ↗ |
| 2023-01-24 | ECKERT R ANDREW | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 6,992 | — | ↗ |
| 2023-01-24 | Byington Carrie L | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 1,924 | — | ↗ |
| 2023-01-24 | Brown William M | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 1,586 | — | ↗ |
| 2023-01-24 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 848 | 0.00 | — | 13,425 | — | ↗ |
| 2023-01-23 | Shan David | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,478 | — | ↗ |
| 2022-12-21 | Khichi Samrat S. | Officer | G-Gift | D | Common Stock | 19 | 0.00 | — | 9,251 | — | ↗ |
| 2022-12-13 | Khichi Samrat S. | Officer | G-Gift | D | Common Stock | 40 | 0.00 | — | 9,270 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Thomas E. Polen Chairman, Chief Executive Officer and President | 1.40M | — | 9.99M | 3.31M | 1.85M | 578.0K | 17.13M | 77.67% | ↗ |
| 2 | 2025 | Christopher J. DelOrefice Executive Vice President and Chief Financial Officer | 837.5K | — | 3.14M | 1.04M | 722.5K | 135.8K | 5.88M | 71.15% | ↗ |
| 3 | 2025 | Michael C. Feld Executive Vice President, Chief Revenue Officer and President, Life Sciences Segment | 775.0K | — | 1.64M | 544.1K | 533.6K | 602.1K | 4.10M | 53.36% | ↗ |
| 4 | 2025 | Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | 768.8K | — | 1.64M | 544.1K | 533.6K | 161.0K | 3.65M | 59.90% | ↗ |
| 5 | 2025 | Richard E. Byrd Executive Vice President and President, Interventional Segment | 756.3K | — | 1.43M | 473.1K | 592.9K | 149.3K | 3.40M | 55.92% | ↗ |
| 6 | 2024 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 1.35M | — | 9.24M | 3.99M | 2.11M | 613.4K | 17.31M | 76.45% | ↗ |
| 7 | 2024 | Thomas E. Polen Chairman, Chief Executive Officer and President | 1.35M | — | 9.24M | 3.99M | 2.11M | 613.4K | 17.31M | 76.45% | ↗ |
| 8 | 2024 | Christopher J. DelOrefice Executive Vice President and Chief Financial Officer | 785.4K | — | 2.69M | 1.16M | 906.4K | 85.6K | 5.63M | 68.42% | ↗ |
| 9 | 2024 | Michael D. Garrison Executive Vice President and President, Medical Segment | 731.3K | — | 1.51M | 653.5K | 556.2K | 168.1K | 3.62M | 59.82% | ↗ |
| 10 | 2024 | Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | 731.3K | — | 1.51M | 653.5K | 556.2K | 168.1K | 3.62M | 59.82% | ↗ |
| 11 | 2024 | Shana Neal Executive Vice President and Chief People Officer | 622.6K | — | 1.34M | 579.4K | 484.5K | 280.3K | 3.31M | 58.07% | ↗ |
| 12 | 2024 | Richard E. Byrd Executive Vice President and President, Interventional Segment | 681.3K | — | 1.18M | 508.2K | 648.9K | 253.6K | 3.27M | 51.55% | ↗ |
| 13 | 2023 | Thomas E. Polen Chairman, Chief Executive Officer and President | 1.32M | — | 9.49M | 4.04M | 1.89M | 570.2K | 17.31M | 78.20% | ↗ |
| 14 | 2023 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 1.32M | — | 9.49M | 4.04M | 1.89M | 570.2K | 17.31M | 78.20% | ↗ |
| 15 | 2023 | Shana Neal Executive Vice President and Chief People Officer | 606.7K | 375.0K | 3.47M | 632.8K | 433.8K | 369.9K | 5.89M | 69.67% | ↗ |
| 16 | 2023 | Christopher J. DelOrefice Executive Vice President and Chief Financial Officer | 736.2K | — | 2.53M | 1.08M | 775.0K | 85.5K | 5.21M | 69.33% | ↗ |
| 17 | 2023 | Michael D. Garrison Executive Vice President and President, Medical Segment | 675.0K | — | 1.28M | 547.1K | 599.6K | 548.2K | 3.65M | 50.12% | ↗ |
| 18 | 2023 | Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | 675.0K | — | 1.28M | 547.1K | 599.6K | 548.2K | 3.65M | 50.12% | ↗ |
| 19 | 2023 | David B. Hickey Executive Vice President and President, Life Sciences Segment | 649.3K | — | 1.49M | 634.4K | 422.5K | 151.0K | 3.35M | 63.46% | ↗ |
| 20 | 2022 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 1.28M | — | 8.89M | 3.74M | 2.49M | 313.8K | 16.71M | 75.57% | ↗ |
| 21 | 2022 | Christopher J. DelOrefice Executive Vice President and Chief Financial Officer | 720.0K | 230.0K | 2.85M | 921.6K | 970.6K | 147.8K | 5.84M | 64.61% | ↗ |
| 22 | 2022 | Alberto Mas Former Executive Vice President and President, Medical Segment | 734.1K | 300.0K | 1.78M | 747.7K | 891.9K | 67.5K | 4.52M | 55.88% | ↗ |
| 23 | 2022 | Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel | 766.9K | — | 1.61M | 676.3K | 931.8K | 132.2K | 4.11M | 55.50% | ↗ |
| 24 | 2022 | David B. Hickey Executive Vice President and President, Life Sciences Segment | 620.0K | — | 1.24M | 520.3K | 765.9K | 118.2K | 3.26M | 53.88% | ↗ |
| 25 | 2022 | Shana Neal Executive Vice President and Chief People Officer | 300.0K | 375.0K | 1.89M | — | 434.2K | 221.0K | 3.22M | 58.71% | ↗ |
| 26 | 2021 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 1.23M | — | 6.23M | 4.10M | 2.36M | 273.7K | 14.19M | 72.79% | ↗ |
| 27 | 2021 | Christopher R. Reidy Executive Vice President and Chief Administrative Officer | 878.3K | — | 2.02M | 1.75M | 1.01M | 152.3K | 5.81M | 64.94% | ↗ |
| 28 | 2021 | Alberto Mas Executive Vice President and President, Medical Segment | 713.5K | — | 1.46M | 1.22M | 848.7K | 92.1K | 4.34M | 61.87% | ↗ |
| 29 | 2021 | Alberto Mas Former Executive Vice President and President, Medical Segment | 713.5K | — | 1.46M | 1.22M | 848.7K | 92.1K | 4.34M | 61.87% | ↗ |
| 30 | 2021 | Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel | 700.8K | — | 1.01M | 883.3K | 724.1K | 210.9K | 3.53M | 53.67% | ↗ |
| 31 | 2021 | Simon D. Campion Executive Vice President and President, Interventional Segment | 612.5K | — | 1.08M | 848.8K | 671.7K | 207.2K | 3.42M | 56.42% | ↗ |
| 32 | 2021 | Christopher J. DelOrefice Executive Vice President and Chief Financial Officer | 60.0K | 450.0K | 1.10M | — | — | 1.6K | 1.61M | 68.16% | ↗ |
| 33 | 2020 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 951.7K | — | 5.64M | 3.75M | 1.09M | 238.9K | 11.67M | 80.43% | ↗ |
| 34 | 2020 | Thomas E. Polen President and Chief Executive Officer | 951.7K | — | 5.64M | 3.75M | 1.09M | 238.9K | 11.67M | 80.43% | ↗ |
| 35 | 2020 | Christopher R. Reidy Executive Vice President and Chief Administrative Officer | 775.9K | — | 2.04M | 1.36M | 582.0K | 165.8K | 4.92M | 69.02% | ↗ |
| 36 | 2020 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 775.9K | — | 2.04M | 1.36M | 582.0K | 165.8K | 4.92M | 69.02% | ↗ |
| 37 | 2020 | Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel | 627.0K | 1.05M | 926.7K | 616.5K | 455.4K | 261.1K | 3.94M | 39.19% | ↗ |
| 38 | 2020 | Alberto Mas Executive Vice President and President, Medical Segment | 665.4K | — | 1.42M | 945.2K | 446.5K | 239.1K | 3.72M | 63.66% | ↗ |
| 39 | 2020 | Alberto Mas Former Executive Vice President and President, Medical Segment | 665.4K | — | 1.42M | 945.2K | 446.5K | 239.1K | 3.72M | 63.66% | ↗ |
| 40 | 2020 | Alberto Mas Executive Vice President and President, Medical | 665.4K | — | 1.42M | 945.2K | 446.5K | 239.1K | 3.72M | 63.66% | ↗ |
| 41 | 2020 | Patrick K. Kaltenbach Executive Vice President, and President, Life | 636.0K | 750.0K | 1.33M | 884.6K | 490.8K | 70.7K | 3.67M | 60.32% | ↗ |
| 42 | 2020 | Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs | 627.0K | 1.05M | 926.7K | 616.5K | 455.4K | 261.1K | 3.48M | 44.31% | ↗ |
| 43 | 2020 | Vincent A. Forlenza Chairman of the Board | 1.09M | — | — | — | 1.35M | 775.8K | 3.21M | 0.00% | ↗ |
| 44 | 2019 | Vincent A. Forlenza Chairman of the Board | 1.28M | — | 7.27M | 4.80M | 1.95M | 724.6K | 16.01M | 75.34% | ↗ |
| 45 | 2019 | Patrick K. Kaltenbach Executive Vice President, and President, Life | 664.6K | 750.0K | 4.14M | 878.8K | 562.4K | 53.4K | 7.05M | 71.18% | ↗ |
| 46 | 2019 | Thomas E. Polen Chairman of the Board, Chief Executive Officer and President | 900.0K | — | 2.35M | 1.55M | 990.0K | 237.6K | 6.03M | 64.72% | ↗ |
| 47 | 2019 | Thomas E. Polen President and Chief Executive Officer | 900.0K | — | 2.35M | 1.55M | 990.0K | 237.6K | 6.03M | 64.72% | ↗ |
| 48 | 2019 | Christopher R. Reidy Executive Vice President and Chief Administrative Officer | 853.9K | — | 1.73M | 1.14M | 850.0K | 163.4K | 4.74M | 60.63% | ↗ |
| 49 | 2019 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 853.9K | — | 1.73M | 1.14M | 850.0K | 163.4K | 4.74M | 60.63% | ↗ |
| 50 | 2019 | Alberto Mas Executive Vice President and President, Medical Segment | 695.3K | — | 1.42M | 939.0K | 588.3K | 597.4K | 4.24M | 55.66% | ↗ |
| 51 | 2019 | Alberto Mas Executive Vice President and President, Medical | 695.3K | — | 1.42M | 939.0K | 588.3K | 597.4K | 4.24M | 55.66% | ↗ |
| 52 | 2019 | Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs | 631.0K | 1.05M | 835.3K | 551.2K | 607.2K | 275.9K | 3.95M | 35.08% | ↗ |
| 53 | 2019 | Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel | 631.0K | 1.05M | 835.3K | 551.2K | 607.2K | 275.9K | 3.95M | 35.08% | ↗ |
| 54 | 2018 | Vincent A. Forlenza Chairman and Chief Executive Officer | 1.19M | — | 6.69M | 4.42M | 1.98M | 684.7K | 14.97M | 74.25% | ↗ |
| 55 | 2018 | Vincent A. Forlenza Chairman of the Board | 1.19M | — | 6.69M | 4.42M | 1.98M | 684.7K | 14.97M | 74.25% | ↗ |
| 56 | 2018 | Thomas E. Polen President and Chief Executive Officer | 849.8K | — | 2.23M | 1.47M | 1.13M | 140.7K | 5.83M | 63.58% | ↗ |
| 57 | 2018 | Thomas E. Polen President and Chief Operating Officer | 849.8K | — | 2.23M | 1.47M | 1.13M | 140.7K | 5.83M | 63.58% | ↗ |
| 58 | 2018 | Patrick K. Kaltenbach Executive Vice President, and President, Life | 216.7K | 2.00M | 1.66M | 1.12M | 205.7K | 18.6K | 5.23M | 53.31% | ↗ |
| 59 | 2018 | Patrick K. Kaltenbach Executive Vice President, and President, Life Sciences | 216.7K | 2.00M | 1.66M | 1.12M | 205.7K | 8.8K | 5.22M | 53.41% | ↗ |
| 60 | 2018 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 818.2K | — | 1.99M | 1.32M | 902.8K | 149.6K | 5.18M | 63.88% | ↗ |
| 61 | 2018 | Samrat S. Khichi Executive Vice President and General Counsel | 450.0K | 1.05M | 1.05M | 692.9K | 371.3K | 20.2K | 3.75M | 46.40% | ↗ |
| 62 | 2018 | Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs | 450.0K | 1.05M | 1.05M | 692.9K | 371.3K | 115.0K | 3.73M | 46.68% | ↗ |
| 63 | 2017 | Vincent A. Forlenza Chairman and Chief Executive Officer | 1.15M | — | 5.64M | 3.79M | 1.80M | 668.7K | 13.06M | 72.26% | ↗ |
| 64 | 2017 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 778.2K | — | 1.64M | 1.10M | 950.0K | 149.8K | 4.62M | 59.39% | ↗ |
| 65 | 2017 | Thomas E. Polen President and Chief Operating Officer | 761.4K | — | 1.49M | 1.00M | 875.0K | 119.7K | 4.25M | 58.71% | ↗ |
| 66 | 2017 | Thomas E. Polen President | 761.4K | — | 1.49M | 1.00M | 875.0K | 119.7K | 4.25M | 58.71% | ↗ |
| 67 | 2017 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 686.8K | — | 1.04M | 702.7K | 603.3K | 122.2K | 3.16M | 55.31% | ↗ |
| 68 | 2017 | Alexandre Conroy President, Worldwide Medication and Procedural Solutions | 576.2K | — | 940.5K | 632.5K | 583.5K | 240.4K | 2.97M | 52.91% | ↗ |
| 69 | 2016 | Vincent A. Forlenza Chairman and Chief Executive Officer | 1.11M | — | 5.72M | 4.57M | 2.00M | 530.8K | 13.93M | 73.90% | ↗ |
| 70 | 2016 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 1.11M | — | 5.72M | 4.57M | 2.00M | 530.8K | 13.93M | 73.90% | ↗ |
| 71 | 2016 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 746.6K | — | 1.53M | 1.22M | 886.3K | 144.9K | 4.52M | 60.71% | ↗ |
| 72 | 2016 | William A. Kozy. Former Executive Vice President and Chief Operating Officer | 386.1K | — | 1.72M | 1.37M | 519.7K | 436.2K | 4.43M | 69.71% | ↗ |
| 73 | 2016 | Thomas E. Polen Executive Vice President and President, Medical Segment | 651.0K | — | 953.7K | 762.1K | 748.6K | 145.4K | 3.26M | 52.62% | ↗ |
| 74 | 2016 | Thomas E. Polen President and Chief Operating Officer | 651.0K | — | 953.7K | 762.1K | 748.6K | 145.4K | 3.26M | 52.62% | ↗ |
| 75 | 2016 | Thomas E. Polen President | 651.0K | — | 953.7K | 762.1K | 748.6K | 145.4K | 3.26M | 52.62% | ↗ |
| 76 | 2016 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 664.4K | — | 953.7K | 762.1K | 617.9K | 126.7K | 3.12M | 54.91% | ↗ |
| 77 | 2016 | Alexandre Conroy Executive Vice President and President, Europe, EMA and Americas | 530.3K | — | 834.6K | 666.9K | 486.9K | 236.6K | 2.76M | 54.49% | ↗ |
| 78 | 2016 | Alexandre Conroy President, Worldwide Medication and Procedural Solutions | 530.3K | — | 834.6K | 666.9K | 486.9K | 236.6K | 2.76M | 54.49% | ↗ |
| 79 | 2015 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 1.05M | — | 5.38M | — | 1.66M | 44.8K | 11.71M | 45.96% | ↗ |
| 80 | 2015 | Vincent A. Forlenza Chairman and Chief Executive Officer | 1.05M | — | 5.38M | 3.58M | 1.66M | 44.8K | 11.71M | 76.50% | ↗ |
| 81 | 2015 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 1.05M | — | 5.38M | 3.58M | 1.66M | 44.8K | 11.71M | 76.50% | ↗ |
| 82 | 2015 | William A. Kozy Executive Vice President and Chief Operating Officer | 749.8K | — | 1.75M | — | 1.00M | 49.5K | 5.17M | 33.84% | ↗ |
| 83 | 2015 | William A. Kozy. Former Executive Vice President and Chief Operating Officer | 749.8K | — | 1.75M | 1.16M | 1.00M | 509.4K | 5.17M | 56.33% | ↗ |
| 84 | 2015 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and | 713.5K | — | 1.36M | — | 712.8K | 48.7K | 3.82M | 35.65% | ↗ |
| 85 | 2015 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 713.5K | — | 1.36M | 904.9K | 712.8K | 126.3K | 3.82M | 59.35% | ↗ |
| 86 | 2015 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 637.3K | — | 972.7K | — | 585.5K | 43.7K | 2.95M | 32.95% | ↗ |
| 87 | 2015 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 637.3K | — | 972.7K | 646.4K | 585.5K | 110.4K | 2.95M | 54.84% | ↗ |
| 88 | 2015 | Jeffrey S. Sherman Executive Vice President and General Counsel | 560.3K | — | 875.5K | — | 458.2K | 48.7K | 2.65M | 33.08% | ↗ |
| 89 | 2014 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 985.0K | — | 4.65M | 3.15M | 1.40M | 791.6K | 10.98M | 71.08% | ↗ |
| 90 | 2014 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 985.0K | — | 4.65M | — | 1.40M | 35.7K | 10.98M | 42.37% | ↗ |
| 91 | 2014 | William A. Kozy Executive Vice President and Chief Operating Officer | 721.0K | — | 1.86M | — | 736.1K | 40.4K | 5.07M | 36.71% | ↗ |
| 92 | 2014 | William A. Kozy. Former Executive Vice President and Chief Operating Officer | 721.0K | — | 1.86M | 1.26M | 736.1K | 490.5K | 5.07M | 61.59% | ↗ |
| 93 | 2014 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer | 690.2K | — | 1.24M | 841.0K | 663.9K | 63.6K | 3.50M | 59.49% | ↗ |
| 94 | 2014 | Christopher R. Reidy Chief Financial Officer and Executive Vice President of Administration | 690.2K | — | 1.24M | 841.0K | 663.9K | 21.5K | 3.50M | 59.49% | ↗ |
| 95 | 2014 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and | 690.2K | — | 1.24M | — | 663.9K | 21.5K | 3.50M | 35.46% | ↗ |
| 96 | 2014 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 615.8K | 285.0K | 806.6K | — | 531.6K | 11.7K | 2.84M | 28.39% | ↗ |
| 97 | 2014 | Jeffrey S. Sherman Executive Vice President and General Counsel | 540.8K | — | 806.6K | — | 409.0K | 39.8K | 2.45M | 32.96% | ↗ |
| 98 | 2014 | Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 540.8K | — | 806.6K | 546.7K | 409.0K | 144.2K | 2.45M | 55.30% | ↗ |
| 99 | 2014 | Jeffrey S. Sherman Senior Vice President and General Counsel | 540.8K | — | 806.6K | 546.7K | 409.0K | 39.8K | 2.45M | 55.30% | ↗ |
| 100 | 2013 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 930.0K | — | 3.76M | — | 1.23M | 36.0K | 9.18M | 40.92% | ↗ |
| 101 | 2013 | William A. Kozy Executive Vice President and Chief Operating Officer | 690.0K | — | 1.84M | — | 865.1K | 39.7K | 5.38M | 34.27% | ↗ |
| 102 | 2013 | Jeffrey S. Sherman Senior Vice President and General Counsel | 516.3K | — | 903.2K | 588.6K | 530.9K | 39.0K | 3.18M | 46.88% | ↗ |
| 103 | 2013 | Jeffrey S. Sherman Executive Vice President and General Counsel | 516.3K | — | 903.2K | — | 530.9K | 39.0K | 3.18M | 28.38% | ↗ |
| 104 | 2013 | Christopher R. Reidy Executive Vice President, Chief Financial Officer and | 144.2K | — | — | — | 131.2K | 4.6K | 286.4K | 0.00% | ↗ |
| 105 | 2013 | Christopher R. Reidy Chief Financial Officer and Executive Vice President of Administration | 144.2K | — | — | — | 131.2K | 4.6K | 286.4K | 0.00% | ↗ |
| 106 | 2012 | Vincent A. Forlenza Chairman, Chief Executive Officer and President | 900.0K | — | 3.44M | 2.29M | 1.08M | 41.8K | 9.42M | 60.88% | ↗ |
| 107 | 2012 | William A. Kozy Executive Vice President and Chief Operating Officer | 643.3K | — | 1.37M | 912.3K | 724.5K | 44.6K | 4.81M | 47.44% | ↗ |
| 108 | 2012 | Jeffrey S. Sherman Senior Vice President and General Counsel | 486.3K | — | 839.9K | 559.4K | 444.3K | 34.3K | 2.48M | 56.41% | ↗ |
| 109 | 2009 | Edward J. Ludwig Chairman and Chief Executive Officer | 1.07M | — | 2.00M | 1.60M | 1.50M | 33.1K | 9.12M | 39.46% | ↗ |
| 110 | 2009 | Vincent A. Forlenza President | 622.5K | — | 627.9K | 556.5K | 625.0K | 36.2K | 3.58M | 33.12% | ↗ |
| 111 | 2009 | William A. Kozy Executive Vice President | 567.2K | — | 479.2K | 385.4K | 470.0K | 35.4K | 3.15M | 27.44% | ↗ |
| 112 | 2009 | John R. Considine Vice Chairman | 692.9K | — | 597.3K | 463.3K | 600.0K | 32.5K | 2.98M | 35.58% | ↗ |
| 113 | 2009 | David V. Elkins Executive Vice President and Chief Financial Officer | 413.5K | 220.0K | 91.0K | — | 350.0K | 78.4K | 1.17M | 7.80% | ↗ |
| 114 | 2008 | Edward J. Ludwig Chairman and Chief Executive Officer | 1.06M | — | 3.00M | 1.92M | 1.53M | 14.3K | 7.52M | 65.40% | ↗ |
| 115 | 2008 | John R. Considine Vice Chairman | 667.2K | — | 955.7K | 599.5K | 675.0K | 11.1K | 3.13M | 49.65% | ↗ |
| 116 | 2008 | Vincent A. Forlenza President | 538.7K | — | 975.8K | 838.6K | 625.0K | 39.6K | 3.02M | 60.13% | ↗ |
| 117 | 2008 | William A. Kozy Executive Vice President | 538.7K | — | 725.8K | 465.4K | 470.0K | 14.0K | 2.21M | 53.81% | ↗ |
| 118 | 2007 | Edward J. Ludwig Chairman and Chief Executive Officer | 1.03M | — | 2.96M | 2.19M | 1.40M | 19.2K | 8.05M | 64.01% | ↗ |
| 119 | 2007 | John R. Considine Vice Chairman | 644.0K | — | 1.03M | — | 670.0K | 7.3K | 3.25M | 31.54% | ↗ |
| 120 | 2007 | Vincent A. Forlenza President | 510.2K | — | 847.4K | — | 585.0K | 7.3K | 2.74M | 30.90% | ↗ |
| 121 | 2007 | William A. Kozy Executive Vice President | 509.2K | — | 855.5K | — | 425.0K | 7.5K | 2.67M | 32.10% | ↗ |
| 122 | 2006 | Edward J. Ludwig Chairman, President and Chief Executive Officer | 1.02M | 1.15M | 990.9K | 86.8K | — | 7.7K | 3.17M | 34.00% | ↗ |
| 123 | 2006 | John R. Considine Senior Executive Vice President and Chief | 620.7K | 500.0K | 321.3K | 28.2K | — | 7.3K | 1.45M | 24.12% | ↗ |
| 124 | 2006 | Gary M. Cohen Executive Vice President | 509.7K | 355.0K | 243.7K | 21.4K | — | 7.1K | 1.12M | 23.76% | ↗ |
| 125 | 2006 | Vincent A. Forlenza Executive Vice President | 476.4K | 340.0K | 241.0K | 21.1K | — | 7.1K | 1.06M | 24.62% | ↗ |
| 126 | 2006 | William A. Kozy Executive Vice President | 472.7K | 340.0K | 241.0K | 21.1K | — | 7.1K | 1.06M | 24.71% | ↗ |
| 127 | 2005 | Edward J. Ludwig Chairman, President and Chief Executive Officer | 978.6K | 1.56M | 804.0K | 76.4K | — | 7.5K | 3.35M | 26.27% | ↗ |
| 128 | 2005 | John R. Considine Senior Executive Vice President and Chief | 594.9K | 650.0K | 321.6K | 30.6K | — | 7.0K | 1.57M | 22.38% | ↗ |
| 129 | 2005 | Gary M. Cohen Executive Vice President | 488.0K | 500.0K | 243.9K | 23.2K | — | 6.9K | 1.24M | 21.56% | ↗ |
| 130 | 2005 | Vincent A. Forlenza Executive Vice President | 453.4K | 450.0K | 241.2K | 22.9K | — | 6.8K | 1.15M | 22.94% | ↗ |
| 131 | 2005 | William A. Kozy Executive Vice President | 449.9K | 450.0K | 241.2K | 22.9K | — | 6.8K | 1.15M | 23.01% | ↗ |
| 132 | 2004 | Edward J. Ludwig Chairman, President and Chief Executive Officer | 933.7K | 1.20M | 537.8K | 99.0K | — | 7.3K | 2.68M | 23.77% | ↗ |
| 133 | 2004 | John R. Considine Senior Executive Vice President and Chief | 575.0K | 480.0K | 217.4K | 40.0K | — | 6.8K | 1.28M | 20.12% | ↗ |
| 134 | 2004 | Gary M. Cohen Executive Vice President | 472.5K | 345.0K | 163.0K | — | — | 6.7K | 987.2K | 16.51% | ↗ |
| 135 | 2004 | Vincent A. Forlenza Executive Vice President | 436.2K | 330.0K | 141.3K | — | — | 6.7K | 914.2K | 15.46% | ↗ |
| 136 | 2004 | William A. Kozy Executive Vice President | 428.7K | 330.0K | 141.3K | — | — | 6.7K | 906.7K | 15.58% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman | 4M | male |
| Michael C. Feld | Executive VP & Chief Revenue Officer | 2M | male |
| Richard Byrd | Executive Vice President & President of Interventional Segment | 1M | male |
| Michael Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 1M | male |
| Pamela L. Spikner | Senior Vice President, Chief Accounting Officer & Controller | — | female |
| Shawn C. Bevec | Senior Vice President of Investor Relations | — | male |
| Claudia Curtis | Senior Vice President, Chief Ethics & Compliance Officer | — | female |
| Vitor Roque | Senior VP of Business Finance & Interim CFO | — | male |
| Denise Fleming | Executive Vice President of Technology & Global Services and Chief Information Officer | — | female |
| Elizabeth McCombs | Executive Vice President & Chief Technology Officer | — | female |
| Joseph Smith | Senior Vice President & Chief Scientific Officer | — | — |
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2024-02-15 | 2024-03-15 | Shelley Moore Capito | WV | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-10-18 | 2021-11-10 | Tommy Tuberville | AL | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2018-04-24 | 2018-05-14 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2018-04-05 | 2018-05-14 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2016-04-19 | 2016-05-04 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-17 | 2026-04-06 | Kevin Hern | OK01 | Joint | Sale | $15,001 - $50,000 | ↗ |
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-24 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-06-17 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-15 | 2025-06-10 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-13 | 2025-06-18 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-04-29 | Rob Bresnahan | PA08 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-03-05 | 2025-04-14 | Jefferson Shreve | IN06 | — | Sale | $15,001 - $50,000 | ↗ |
| 2024-09-11 | 2024-09-25 | William R. Keating | MA09 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-09-09 | 2024-10-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2024-09-04 | 2024-09-06 | John James | MI10 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-05-24 | 2024-06-18 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-25 | 2024-04-05 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-21 | 2024-04-05 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2024-01-11 | 2024-02-20 | Thomas H. Kean | NJ07 | Self | Purchase | $1,001 - $15,000 | ↗ |
| 2024-01-10 | 2024-02-05 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-01-03 | 2024-02-05 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-11-10 | 2024-09-02 | John James | MI10 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Sale | $15,001 - $50,000 | ↗ |
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
